Related Experiment Video
Updated: May 31, 2025

Studying Food Reward and Motivation in Humans
Published on: March 19, 2014
The Ethics of Ozempic and Wegovy
Nanette Ryan1, Julian Savulescu2,3
1National University of Singapore Centre for Biomedical Ethics, Singapore.
Abstract:
Semaglutide, sold under the brand names of Ozempic, Rybelsus and Wegovy, is one of the most popular drugs on the market. Manufactured by Novo Nordisk, semaglutide is the newest in a family of glucagon-like peptide-1 receptor agonists used most commonly to treat type II diabetes. To date, the results of semaglutide for the treatment of type II diabetes have been overwhelmingly positive. It is for the drug's effects on appetite suppression and weight loss, however, that have led its surge in popularity, with many hailing semaglutide as the new 'miracle drug for weight loss'. Despite its popularity, both the governmental and popular reception to the drug has largely been mixed. In this paper, we address a range of ethical concerns and argue that while many are legitimate, they do not provide conclusive reason not to prescribe semaglutide for weight loss.
More Related Videos
12:08Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
06:14Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients
Published on: October 15, 2017
Related Concept Videos
Ethical Issues
Ethical Concerns in Healthcare:
Ethics and Bioethics
Oral Hypoglycemic Agents: Biguanides and Glitazones
Ethics in Research
Ethical Dilemmas II
Ethical Dilemmas I
Let us explore some examples to understand the potentially complex moral decisions nurses face.
Take the case of caring for minors, particularly in areas related to reproductive...